SQore[™] Enabled High Concentration mAb Formulations for Subcutaneous Delivery


Comera

LIFE SCIENCES

Yuhong Zeng, PhD October 16, 2023 PODD




Leading a <u>compassionate new era</u> in medicine.




PODD: Partnership Opportunities in Drug Delivery

Challenges with Concentrated mAb Formulations



Impacts of Attractive Protein-Protein Interactions (PPIs)



PODD: Partnership Opportunities in Drug Delivery

Comera

LIFE SCIENCES

SQore Viscosity Reduction Platform



- Identifies driving forces for high viscosity
- Selects excipients inhibiting attractive interactions
- Expertise in formulation design


Successfully tested with >45 mAbs at high concentration, resulting in viscosity reduction up to 85%

- Viscosity reduction benefits and preclinical PK/safety data for the lead SQore[™] excipient have been published in a peer-reviewed journal showing favorable PK/safety results
- Robust IP portfolio, with 18 patents issued and >35 patents pending, covering 3 patent families: viscosity reduction, stabilization and processing

PODD: Partnership Opportunities in Drug Delivery

omera

Caffeine: Effects on mAb Viscosity and PK Profiles






Notes

Preclinical Pharmacokinetic Study on Caffeine as an Excipient for Monoclonal Antibody Formulations

Yuhong Zeng*, Subhashchandra Naik, Timothy Tran, Philip Wuthrich, Neal Muni, Robert P. Mahoney

Comera Life Sciences, Inc., 12 Gill Street Suite 4650, Woburn, MA 01801, USA



https://jpharmsci.org/article/S0022-3549(21)00348-8/fulltext

https://jpharmsci.org/article/S0022-3549(23)00299-X/fulltext

PODD: Partnership Opportunities in Drug Delivery

Comera

LIFE SCIENCES

Thank you!

Comera Life Sciences 12 Gill Street, Suite 4650 Woburn, MA 01801, USA comeralifesciences.com